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PSORS lociThere are major gaps in our knowledge regarding the exact mechanisms and genetic basis of psoriasis. To
investigate the pathogenesis of psoriasis, gene expression in 10 skin (5 lesional, 5 nonlesional) and 11
blood (6 psoriatic, 5 nonpsoriatic) samples were examined using Affymetrix HG-U95A microarrays. We
detected 535 (425 upregulated, 110 downregulated) DEGs in lesional skin at 1% false discovery rate
(FDR). Combining nine microarray studies comparing lesional and nonlesional psoriatic skin, 34.5% of dys-
regulated genes were overlapped in multiple studies. We further identiﬁed 20 skin and 2 blood associated tran-
scriptional “hot spots” at speciﬁed genomic locations. At 5% FDR, 11.8% skin and 10.4% blood DEGs in our study
mapped to one of the 12 PSORS loci. DEGs that overlap with PSORS loci may offer prioritized targets for down-
stream genetic ﬁne mapping studies. Novel DEG “hot spots”may provide new targets for deﬁning susceptibility
loci in future studies.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Psoriasis is a chronic systemic inﬂammatory disorder involving
the skin, nails and occasionally the joints that affects approximately
2% of the Caucasian population [1,2]. The most characteristic feature
of psoriasis is the thick scaly plaque resulting from the hyper-
proliferation of keratinocytes. Investigations over the last two de-
cades have described many key points in disease pathogenesis and
recent ﬁndings have emphasized the roles of Th1 and Th17 cells
along with dendritic cells in the complex interplay between the im-
mune system and keratinocyte activity that underlies the hyper-
proliferation [1–3].
The etiology of psoriasis is complex, involving both environmental
and genetic factors. Linkage and association studies have reported
nearly 40 susceptibility loci for psoriasis, 12 of which (PSORS1-12)
have been conﬁrmed by multiple studies. However, a comprehensive
list and exact locations of susceptibility genes that would account for
the development of psoriasis has not been generated, and there re-
main several gaps in our knowledge regarding the mechanisms by
which putative susceptibility genes interact with one another and
with environmental factors to initiate plaque formation.
Microarray methods have been employed frequently over the past
decade by several groups to explore the psoriatic lesional ‘transcriptome’msu.edu (M. Icen),
rights reserved.[4–13]. There have also beenmicroarray studies exploring in vivo and in
vitro treatment effects on gene expression in the blood of subjects with
psoriasis and a recent publication compared the gene expression in pso-
riatic blood to blood from healthy subjects. Chen et al. have recently per-
formed an analysis on the results of microarray studies and shown that
the differentially expressed genes (DEGs) were more likely than con-
stantly expressed genes to be associated with disease. They have also
reported that the chances of a gene to be associated with disease in-
creased exponentially as the differential expression ratio (number of
studies reporting it a gene as a DEG divided by the number of studies
measuring the gene) increased and proposed the utilization of gene ex-
pression data to prioritize target candidate genes or single nucleotide
polymorphisms in genome wide association studies [14].
In this study, we investigated the differential gene expression be-
tween lesional and nonlesional psoriatic skin samples to identify dis-
ease associated dysregulated pathways at the local tissue level. We
also explored the degree of consensus among published microarray
gene expression studies and our data to illuminate signiﬁcant signa-
tures not evident in the analysis of individual datasets. The group of
DEGs shared across multiple studies highlights key genes and path-
ways of dysregulation that are consistent with the pathophysiologic
changes taking place in the psoriatic plaque. Speciﬁcally, replicated
DEGs reinforce the importance of dysregulation in 1) epidermal dif-
ferentiation, 2) immune response, and 3) hypermetabolic processes
in plaque formation. We also examined the gene expression in the
blood of psoriatic subjects with blood from nonpsoriatics to deﬁne
the disease-associated signatures at the systemic level. In psoriatic
19A.B. Coda et al. / Genomics 100 (2012) 18–26blood, we detected several modulations of gene expression associated
with pathophysiologic pathways previously implicated in psoriasis,
including immune response, proteolysis, apoptosis and oxidation–
reduction. We also evaluated the distribution of our psoriatic skin
and blood associated DEGs, along with the DEGs commonly reported
in previous microarray studies on the genome to investigate their
overlap with the PSORS loci. We further explored the chromosomal
distribution of the genes in these three sets to detect transcriptional
“hot spot” regions where DEGs were found to map signiﬁcantly more
frequently than should occur by chance. The “hot spots”we detected
for the skin and blood DEGs found in our study and the set of DEGs
replicated across microarray studies, their overlaps with each other
and the PSORS loci could be expected to facilitate the pinpointing
of disease-associated genes. The novel “hot spots” detected in our
study may suggest previously unidentiﬁed chromosomal regions
that harbor additional psoriasis susceptibility genes.2. Results
2.1. Unsupervised clustering distinguishes lesional from nonlesional pso-
riatic skin
We initially analyzed themRNA expression in 5 pairs of lesional and
nonlesional skin biopsies from subjects with chronic plaque psoriasis.
After low-level analysis and normalization, 3832 probes fulﬁlled the ﬁl-
tering criteria of coefﬁcient of variation≥0.3 and present call≥30%.
Unsupervised clustering (dChip) resulted in distinct separation of-3.0 -2.5 -2.1 -1.6 -1
Fig. 1. Unsupervised clustering diagram of the genes expressed in lesional and nonlesion
nonlesional samples, which are segregated into distinct clusters. The diagram shows 38
call≥30%, with a clearly distinctive group of 1119 upregulated and 221 downregulated
blood samples obtained from psoriatic and nonpsoriatic subjects. Using the same ﬁlterin
a segregation of cases and controls was not observed with unsupervised clustering. LL, leslesional and nonlesional skin samples (Fig. 1). The upregulated genes
were associated with 93 gene ontology (GO) terms, includingmetabolic
and catabolic activities, cell cycle processes, cutaneous differentiation
and apoptosis (Supplemental File 1).
2.2. Evaluation of DEGs in skin supports known pathological changes
associated with psoriasis
We identiﬁed DEGs in the skin by comparing the log-transformed
expression indices of lesional and nonlesional samples with a paired
t-test (p≤0.01) and a false discovery rate (FDR) was controlled at
1–5% levels using the Benjamini–Hochberg procedure. At 1% FDR we
identiﬁed 535 DEGs in the skin, 425 of which were upregulated and
110 which were downregulated (Supplemental File 2).
From the list of differentially expressed genes, TGM, POLE3, IVL,
FABP5, IL1RN, LYN, GARS and ALOX12B were randomly selected for
evaluation by QRT-PCR in order to validate the results of the microar-
ray analysis. QRT-PCR results uniformly conﬁrmed the dysregulation
of the genes relative to nonlesional skin found by microarray (Supple-
mental File 3).
When we analyzed the 425 upregulated genes in the skin for GO
terms, the highest odds ratios were detected for terms associated with
the hyperproliferative environment of the psoriatic lesion, which can
be grouped in three major categories: 1) cutaneous differentiation, 2)
cell cycle, and 3) metabolic processes. For the 111 downregulated
genes, there were 8 signiﬁcantly enriched GO terms, including oxygen
binding, channel activities, heme and tetrapyrrole binding, nervous
system development and transducer activities.PS4LL
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al psoriatic skin.Unsupervised clustering clearly differentiates between lesional and
32 probes passing the ﬁltering criteria of coefﬁcient of variation≥0.3 and present
genes in lesional skin. We similarly used unsupervised clustering to evaluate the
g criteria, we identiﬁed 1485 probes corresponding to 1353 unique genes. However,
ional skin; NL, nonlesional skin.
20 A.B. Coda et al. / Genomics 100 (2012) 18–26Althoughwe foundno immune-relatedGO terms signiﬁcantly associ-
ated with our list of 535 DEGs, 50 of these genes (9.3%), 44 upregulated
and six downregulated, were associated with immune response func-
tions. Nine of these immune-related genes were among the 22 genes
upregulated more than ﬁve-fold (Fig. 2). Several of the highly
upregulated genes, including SERPINB4, S100A9, S100A7, DEFB4 and PI3,
are known to be released by keratinocytes in response to both adaptive
(IL-17) and innate (IL-1α [12]) immune stimuli. There were seven
other DEGs (S100A8, SPRR2D, CRABP2, NAV3, CXCL1, STAT3 and TGFB1)
in our list known to be upregulated by IL-17. We also detected nine
upregulated genes associated with type 1 interferon signaling (IFI27,
TYMP, IRF7, LAMP3, IFI16, TAP1,MYD88, GCH1 andRPS6KA1).We detected
seven upregulated genes associated with T cell differentiation and
activation (PPP3CB, DPP4, B2M, TGFB1, SYK, PRKDC and FKBP1B).Fig. 3. Overlaps between our dataset and the results of previous studies.Numbers in
parenthesis refer to upregulated/downregulated genes in each region. In the overlap
regions with genes dysregulated in opposite directions, counts refer to the smaller
group number. Group I contains the DEGs between lesional (LL) and nonlesional
(NL) psoriatic skin detected in our study at 1% false discovery rate. § Group II contains
all DEGs in LL vs NL psoriatic comparisons reported by Oestreicher et al., Zhou et al.,
Kulski et al., Mee et al., Reischl et al., Yao et al., Gudjonsson et al. and Suarez-Farinas
et al. * Group III contains the DEGs between LL vs nonpsoriatic (NN) skin reported
by Zhou et al., Kulski et al. and Gudjonsson et al. a JUP is upregulated in our dataset
and downregulated in Gudjonsson et al.'s LL vs NN comparison. b SNX1 is upregulated
in our dataset and downregulated in Gudjonsson et al. and Suarez-Farinas et al.'s LL vs
NL and Gudjonsson et al.'s LL vs NN comparisons. TRBC1///TRBC2 was downregulated
in our dataset and upregulated in Zhou et al.'s LL vs NL and LL vs NN comparisons.
SFPQ was upregulated in two LL vs NL (ours and Zhou et al.'s) and two LL vs NN com-
parisons (Zhou et al. and Kulski et al.) but Kulski et al. also detected the same gene as
downregulated in the LL vs NN comparison. c KRT2 was upregulated in our dataset
and downregulated in Mee et al's, RAB2A was upregulated in our dataset and down-
regulated in Suarez-Farinas et al.'s, UBE2I was upregulated in our and Oestreicher et al.'s
but downregulated in Suarez-Farinas et al.'s dataset. d SFN was downregulated in Zhou
et al's and upregulated in Gudjonsson et al.'s and VAPA was upregulated in Kulski et al.'s
anddownregulated inGudjonsson et al.'s LL vsNN comparisons, e SPRR2Cwasupregulated
inMee et al., Yao et al.'s, Gudjonsson et al. and Suarez-Farinas et al.'s LL vs NL comparisons
and Gudjonsson et al. and Kulski et al.'s LL vs NN comparisons but downregulated in Zhou
et al.'s LL vs NL comparison. f ALG13was reported as both upregulated and downregulated
in Suarez-Farinas et al.'s dataset.2.3. Consensus of DEGs across skin microarray studies
We ran a query in PubMed to ﬁnd previous reports investigating
differential gene expression between lesional and nonlesional psoriatic
skin and identiﬁed 8 published studies (Oestreicher et al. [6], Zhou et al.
[4], Kulski et al. [7], Mee et al. [12], Reischl et al. [11], Yao et al. [10],
Gudjonnson et al. [9] and Suarez-Farinas et al. [13]) using microarray
methods. Because some of these previous studies were executed on
different array platforms, we masked the reported genes that were
not included on the Affymetrix HG-U95A arrays used in our study. In
the lesional vs. nonlesional psoriatic skin comparisons, the eight studies
we included in the comparison group reported a total of 1296 unique
genes that were present on the HG-U95A array. In addition, Zhou
et al., Kulski et al. and Gudjonnson et al. also compared lesional psoriatic
skin to nonpsoriatic control skin andwemerged these two lists together
to form another group with 858 unique genes.
Fig. 3 shows the overlaps between our list of 535 DEGs (Group I),
previously reported DEGs in lesional vs. nonlesional (1296 genes on
the HG-U95A array, Group II) and previously reported lesional vs. non-
psoriatic (858 genes, Group III) comparisons. There are 180 genes
(33.6%) in our list which overlap with DEGs detected in previous
lesional vs. nonlesional comparisons, and 156 genes that were detected
in lesional vs. nonpsoriatic comparisons. There were 125 genes consis-
tently identiﬁed in all three groups and 12 of these genes, ALOX12B,
IVL, TGM3, SPRR1A, S100A7, TGM1, SPRR2D, SPRR1B, KRT6A, FABP5,
CRABP2 and KRT16were associated with GO terms related to epidermal
development and differentiation. In addition, 12 of these 125 genes
were associated with immune response. Also among the overlapping
125 genes, there were 9 genes upregulated by IL-17 (S100A7, S100A8,
S100A9, CRABP2, PI3, SERPINB3, SPRR2D, CXCL1 and DEFB4).
Among the 1651 unique DEGs reported in the lesional vs. non-
lesional comparisons by others and ourselves (union of groups I and IIFig. 2. Skin DEGs with the highest fold changes.Top 22 upregulated genes with fold
changesmore than 5 in skin. Genes in bold are associated with immune related functions.
Complete list of skin DEGs with additional information is in Supplemental File 2.in Fig. 3), there were a total of 570 genes identiﬁed in more than one
study, 366 as upregulated (142detected in our study) and 196 as down-
regulated (33 detected in our study) consistently. Among the 366
replicated genes thatwere consistently upregulated, 26were annotated
for ‘apoptosis’, 26 for ‘oxidation reduction’ and 7 for ‘angiogenesis’. We
also detected 39 genes related to the type 1 interferon pathway and 5
genes that were regulators of NFκB pathway (TNFSF10, IL1B, MALT1,
UBE2N and HMOX1) in this list. Evaluating the functional annotations
of the 196 shared genes that were downregulated, we found signiﬁcant
associations for 10 genes annotated for fatty acid and 29 genes for lipid
metabolic processes, and 11 genes for the term oxidation reduction.2.4. Gene expression in psoriatic blood
In order to identify the DEGs in blood (between six psoriatic and
ﬁve nonpsoriatic samples), log-transformed expression indices of
the samples were compared with unpaired t-test and FDR 1–5%. We
identiﬁed 32 DEGs (7 upregulated and 25 downregulated) that distin-
guished cases from controls at 1% FDR (Table 1), and 153 DEGs (41
upregulated and 112 downregulated) at 5% FDR (Supplemental File
4). Psoriatic blood DEGs did not show signiﬁcant association with
any GO terms at 1% or 5% FDR levels. Nevertheless, there were several
DEGs associated with pathophysiologic pathways implicated in psori-
asis. Of the 153 DEGs we detected at 5% FDR, 15 (9.8%) genes were as-
sociated with immune system functions with 9 upregulated (22.0% of
the upregulated genes) and 6 downregulated genes (5.35% of the
Table 1
Dysregulated genes in psoriatic blood. List of 35 genes differentially expressed between
psoriatic and nonpsoriatic blood at the 1% FDR level.
Gene symbol Accession Gene title Fold
change
Upregulated
KIAA0040 Z99715 KIAA0040 1.58
TOP3B D87012 Topoisomerase (DNA) III beta 1.51
NAB1 AF045451 NGFI-A binding protein 1
(EGR1 binding protein 1)
1.42
ATG13 AB014552 Autophagy related 13 homolog 1.38
MCM3AP AB011144 Minichromosome maintenance complex
component 3 associated protein
1.24
GTF2B M76766 General transcription factor IIB 1.19
LMTK2 AI971726 Lemur tyrosine kinase 2 1.16
Downregulated
C2CD3 AL080220 C2 calcium-dependent domain containing 3 0.83
SLC6A7 S80071 Solute carrier family 6 (neurotransmitter
transporter, L-proline), member 7
0.81
SLC35A3 AB021981 Solute carrier family 35
(UDP-N-acetylglucosamine
(UDP-GlcNAc) transporter),
member A3
0.8
LYPLA2 AL031295 Lysophospholipase II 0.8
MUC3A AF007194 Mucin 3A, cell surface associated 0.8
SNX27 AW024812 Sorting nexin family member 27 0.8
FLT3LG U04806 fms-related tyrosine kinase 3 ligand 0.79
FDXR J03826 Ferredoxin reductase 0.78
IDH3A U07681 Isocitrate dehydrogenase 3 (NAD+) alpha 0.78
TOP2A J04088 Topoisomerase (DNA) II alpha 170 kDa 0.78
FIG4 D87464 FIG4 homolog (S. cerevisiae) 0.77
NR0B2 L76571 Nuclear receptor subfamily 0, group B,
member 2
0.75
IGFBP1 M74587 Insulin-like growth factor binding protein 1 0.73
NAGPA AF052111 N-Acetylglucosamine-1-phosphodiester
alpha-N-acetylglucosaminidase
0.71
PSKH1 AI767675 Protein serine kinase H1 0.7
STX16 W28230 Syntaxin 16 0.67
EPM2AIP1 AB018309 EPM2A (laforin) interacting protein 1 0.67
NHP2L1 Z83840 NHP2 non-histone chromosome protein
2-like 1 (S. cerevisiae)
0.67
PLIN AB005293 Perilipin 0.66
TPM3 X04201 Tropomyosin 3 0.66
STAT2 U18671 Signal transducer and activator of
transcription 2, 113 kDa
0.65
CASP2 U13022 Caspase 2, apoptosis-related cysteine
peptidase
0.63
OXCT1 U62961 3-Oxoacid CoA transferase 1 0.63
NCRNA00084 AW006742 Non-protein coding RNA 84 0.56
– AI817548 – 0.47
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ciated with lipid and fatty acid metabolism, 10 (6.5%) with apoptosis
and 9 (5.9%) with proteolysis. Nine DEGs detected in psoriatic blood,
1 upregulated and 8 downregulated, were associated with oxidation–
reduction functions and 6 genes, 4 of which were upregulated, were
annotated for response to oxidative stress (Fig. 4). There were 2
upregulated genes, CD2 and TRA@, associated with the IL17 signaling
pathway based on functional annotations listed on the DAVID website
(www.david.abcc.ncifcrf.gov).
In the comparison of psoriatic skin and blood DEGs detected in our
analyses, we found seven genes that were upregulated (RANGAP1,
RNF40, SNX1, ISG15, MAP2K5, AP3B1 and DNPEP) and six genes that
were downregulated (TMEM63A, SLC11A2, SFPQ, MYH11, YIPF6 and
N4BP2L2) in both datasets at 5% FDR. Two upregulated (BCR and
APOM) and 15 downregulated genes (ACPP, OXCT1, IDH3A, FIBP,
BTF3L1, POP4, TOP2A, RABIF, PPP2R5E, BCL7B, DVL3, FLT3LG, SERBP1, DPT
and PPFIA1) in the blood were dysregulated in the opposite direction
in the skin.
We also compared our list of blood DEGs to the 25 upregulated and
25 downregulated genes with the highest dysregulation reported byLee et al. [15] but found no overlap between the two datasets. In order
to search for genes commonly dysregulated in systemic comorbidities
that have been linked to psoriasis, we further compared our list of
DEGs in psoriatic blood with the results of two gene expression studies
comparing blood of subjects with and without coronary artery disease.
There were no overlaps between our list of blood DEGs at 5% FDR and
that reported by Sinnaeve et al. [16]. Seven genes from the list of DEGs
reported by Wingrove et al. [17] were included in our set. However,
only LAIR1 was upregulated in both sets and the remaining six genes
(SASH1, CDK11A, ACPP, PPFIA1, CYP4F2 and DEC1) were downregulated
in psoriasis and upregulated in coronary artery stenosis.
2.5. Mapping of DEGs to the genome
We evaluated the chromosomal distribution of psoriasis skin and
blood DEGs across the genome and compared their localizations to
the 12 PSORS loci reported by linkage and association studies [18–27].
At the 1% and 5% FDR levels, 64 of 535 (12.0%) and 159 of 1529
(11.8%) of the skinDEGs correspond to one of these 12 loci, respectively.
In addition, 18 of the 153 (10.4%) DEGs we identiﬁed at 5% FDR in pso-
riatic blood also map to PSORS loci. The highest number of DEGs in the
skin are detected at 1q21 (PSORS4) and 19p13 (PSORS6), with 15 and
14 genes at 1% FDR, and 25 and 32 genes at 5% FDR levels, respectively.
At the 5% FDR level, we also detected 22 and 20 DEGs at PSORS8 and
PSORS11, respectively. The complete list of DEGs from our study that
maps to PSORS loci is presented in Supplemental File 5. We also evalu-
ated the overlap of the 570 genes shared across skin microarray studies
to the PSORS loci and found 67 DEGs mapping to the 12 susceptibility
loci (Supplemental File 6). PSORS4 was the loci where most of the
shared genes were located with 11 genes mapping to this region, in-
cluding members of the S100 and SPRR families IVL and CRABP2, being
reported by more than 5 studies.
Next, we used the ‘genome’ tool in dChip to identify the genomic
regions where DEGs cluster more frequently than would be expected
to occur by chance. Using a threshold of p≤0.0001, we ﬁrst mapped
the skin DEGs from our study at 1% FDR level and identiﬁed four tran-
scriptional “hot spots”: 1q21.1-25.3 (which contains PSORS4),
6p25.3-p24.3, 11q12.1-q13.2 and 16p11.2. When we repeated the
analysis at 5% FDR level, we identiﬁed 20 “hot spots”, 2 of which over-
lap with the conﬁrmed susceptibility loci PSORS4 and PSORS11, and 4
with previously suggested loci at 3p21-23, 9q34, 12q13.2, and 13q21-
32 [19,22,28]. We also detected 14 novel regions where DEGs are sig-
niﬁcantly over-represented. DEGs in these transcriptional “hot spot”
regions are listed in Supplemental File 7.
We detected two regions of signiﬁcant accumulation for blood
DEGs at 6p25.1-p25.2 and 11q12.2-q13.4. These two regions over-
lapped with two of the four “hot spots” identiﬁed for skin DEGs at
1% FDR. Fig. 5 shows the distribution of all “hot spots” for blood and
skin DEGs detected in our analysis along with their overlaps with
one another and with reported disease susceptibility loci.
For the 570 genes replicated across the eight microarray studies
comparing lesional and nonlesional skin, at the p≤0.0001 threshold
we identiﬁed 6 “hot spots” at 1q21.1-q24.2, 4q13.2-q21.1, 10q22.3-
q23.33, 11q12.1-q13.2, 18q21.33 and 19q13.32-q13.33 (Fig. 6).
These “hot spots” overlap with one conﬁrmed (PSORS4 at 1q21)
and two reported (4q13 [29] and 4q21 [19]) susceptibility loci. The
replicated genes are also signiﬁcantly frequent at a region over-
lapping both our skin and blood data at 11q12.1-q13.2.
3. Discussion
In this study, we compared global gene expression between
lesional and nonlesional psoriatic skin samples and conﬁrmed the
distinction between the two skin types. Unsupervised clustering
clearly differentiated cases from controls and the upregulated genes
driving this difference were mainly related to functions associated
Fig. 4. Psoriatic blood DEGs associated with pathophysiologic pathways implicated in psoriasis.
22 A.B. Coda et al. / Genomics 100 (2012) 18–26with epidermal differentiation, cell cycle and metabolism, which are
consistent with the pathophysiologic changes related to the hyper-
metabolic epidermis in the psoriatic plaque. The list of 535 DEGs
detected at 1% FDR was also signiﬁcantly associated with epidermal
differentiation, cell cycle and metabolism functions, as seen for the
upregulated genes in unsupervised clustering analysis.
Functional relevance of reported DEGs to disease processes may be
strengthened by consensus across similar studies. Previous comparisons
of microarray analyses in psoriasis have arrived at contradicting conclu-
sions. While Romanowska [30] reported a high concordance rate with
the results of Zhou et al. [4], Kulski et al. [7], who compared their results
with three earlier studies [5,6,31], claimed concordance to be ‘at best
only moderate’. Gudjonsson et al. [9] detected a ‘limited’ overlap in theFig. 5. Genomic “hot spots” for the skin and blood DEGs.With the use of the ‘genome’ tool in dC
than it would occur by chance. The ﬁgure shows the “hot spots” for DEGs detected in the blood
of skin and blood DEGs detected at 5% FDR in the “hot spots” and the overlapping susceptibility
identiﬁed for the skin at 1% FDR. Complete list of genes mapping to these “hot spots” are listedcomparison of their dataset with two earlier lesional vs nonlesional pso-
riatic skin analyses [4,6], but reported a higher concordance with a more
recent study by Yao et al. [10] performed on the same microarray plat-
form. In a recent report, Suarez-Farinas et al. [13] compared their dataset
to the results of 3 previous microarray studies [4,9,10] with the gene set
enrichment analysismethod. They demonstrated a higher degree of con-
sensus that was not evident in the comparisons of the reported DEG lists
by evaluating each set of DEGs ranked according to fold changes to the
complete probe list in their study, rather than only the identiﬁed set of
DEGs. We also observed a moderate level of concordance, both between
our dataset and the results of previous studies, and across the nine
datasets included in our cross-comparison. There were 180 (33.6%)
DEGs among the 535 we detected that were reported by at least onehip, it is possible to identify the genomic regions where DEGs are locatedmore frequently
at 5% FDR (l, skin at 1% (yellow) and skin at 5% FDR (green). The table presents the number
loci reported previously for that region. Skin “hot spots” in bold overlap with “hot spots”
in Supplemental File 7.
Fig. 6. Genomic “hot spots” for the skinDEGs replicated inmicroarray studies.Chromosomal “hot spots” of the top 570DEGs are noted as bolded blue vertical bars. p-Valueswere calculated
for all stretches containing b or=20 differentially expressed genes to assess the signiﬁcance of “gene proximity”. 335 of the 570 are located signiﬁcant stretches (of b or=20 genes) with
pb0.0001were considered “hot spots” of statistical signiﬁcance. * 11q12.1-q13.2 overlapswith a regionwe detected as a hot spot for both our skin and blood DEGs in our analysis. ** 18q21
and 19q13 were two regions where Gudjonsson et al. also reported an accumulation of highly overexpressed genes in his dataset, which were very similar to the genes we found in these
two regions.
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on different microarray platforms, we ﬁltered the reported datasets to
include only those genes included on the HU-G95A array. Of the 1651
DEGs reported by nine lesional vs. nonlesional comparisons, only 34.5%
were replicated in at least one other study.
A lack of consensus between microarray datasets from different
studies on given disorders has been previously discussed by our
group and others [13,32]. In addition to the random noise associated
with high throughput analysis and differences in experimental and
technical methods used [9,33], the limited consensus in psoriasis
may also relate to heterogeneity of subjects across studies. A recent
study employing RNA-seq also demonstrates the lack of consensus,
with only 44% of their genes overlapping with previous microarray
studies [34]. Differences in methods, which may be exempliﬁed by
demographic differences between the subjects and the criteria used
across microarray studies to deﬁne and report DEGs, also includes
the microarray platforms used, which may vary in the number and
actual location of the probes used for the same regions of the trans-
criptome. The list of 570 genes that are replicated across the nine
studies included in our analysis may provide a distilled set of core
genes that are particularly relevant to lesional pathology.
Although our dataset conﬁrmed signiﬁcant functional pathway asso-
ciations for epidermal hyperproliferation, we found no signiﬁcant asso-
ciation with immune response functions and the numbers of genes
related to the recently emphasized pathways in psoriasis, including
Th1, Th17 anddendritic cells alongwith IL23, NFκB and type 1 interferon
signaling [1–3,10,22,35,36], were somewhat limited. One possible rea-
son that would prevent the detection of signiﬁcant associations with
these pathways may be lack or absence of probes for the related genes
on the microarray platform [13]. In a review of microarray studies,
Kunz noted the absence of IL-17, IL-22 and IL-23 in psoriasis reports
and mentioned the low level of these cytokines they detected in rheu-
matoid arthritis with the microarraymethod [37]. Lack of signiﬁcant as-
sociations with these immune related pathways may also be due to
either a weak immune response in the lesional psoriatic skin, or, possi-
bly, an already active immune response in the nonlesional skin, setting
a high baseline that may have masked the extent of the response in
the lesional samples. In fact, whenwe analyzed the group of 858 uniquegenes reported by Zhou et al., Kulski et al. and Gudjonsson et al. in their
lesional psoriatic vs. nonpsoriatic skin comparisons (Group 3 in Fig. 4),
we did see signiﬁcant associations with immune response related GO
terms ‘regulation of immune system process’, ‘immune response’ and
‘immune system process’. Among these 858 genes, 137 were associated
with immune system processes, indicating that there indeed is an active
immune response in the psoriatic plaque that is not evident in the
lesional vs. nonlesional comparison. When we further analyzed the
group of 228 unique genes reported by the same three studies to be dif-
ferentially expressed in the nonlesional psoriatic vs. nonpsoriatic skin
comparison in order to see the immune response functions, we found
signiﬁcant associations with GO terms ‘response to other organism’
and ‘response to biotic stimulus’, related to 14 genes (DEFB4, DNAJB6,
HSPA8, PPBP, CREB3L1, IFI44, IFNGR1, MX1, MYD88, PLSCR1, S100A12,
S100A7, STAT1 and TRIM22).
These associations indicate an already evident immune activity in
nonlesional psoriatic tissue. Gudjonsson et al. have recently reported
the upregulation of genes associated with innate immunity, including
DEFB4, RNASE7 and IL36G, in the nonlesional psoriatic skin compared
to nonpsoriatic skin [38] which appears to represent a ‘pre-psoriatic’ or
‘stand-by’ state. Expression of angiogenetic markers, vascular volume
and adhesionmolecules are all increased in phenotypically normal pso-
riatic skin, consistentwith the observation that the earliest recognizable
change in psoriasis is the perivascular accumulation of mononuclear
leucocytes [39]. If the immune response activity is already set at a
high level in the nonlesional skin, dysregulation of a limited number
genes may be sufﬁce to initiate plaque formation. The list of commonly
replicated genes in lesional vs. nonlesional skin comparisons may sug-
gest new targets for treatment that would prevent the conversion
from ‘pre-psoriatic’ to active phase.
We also compared the blood frompsoriatic subjects to the blood from
nonpsoriatics to detect the differences in gene expression associated
with psoriasis at the systemic level. The number of DEGs and the range
of associated fold changes we detected in the blood were limited com-
pared to the differences observed between lesional and nonlesional
skin. Comparison of the gene expression between psoriatic and healthy
blood reported by Lee et al. [15] also reported a relatively short list of
DEGs between psoriatic and normal blood, with a narrow range of fold
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overlaps between our set of blood DEGs and list of genes reported by Lee
et al. As might be expected, the transcriptional changes observed in
lesional psoriatic skin were not directly reﬂected in psoriatic blood. Yet,
there were several DEGs in the blood related to the dysregulated path-
ways implicated in psoriasis pathophysiology including immune func-
tion, apoptosis, proteolysis, and lipid and fatty acid metabolism. We
also detected eight downregulated genes associated with oxidation re-
duction processes, which may indicate an increased oxidative stress op-
erative at the systemic level. Reactive oxygen species interfere with
various signaling pathways involved in psoriasis, including MAPK/AP-1,
NFκB and JAK/STAT [40].
Although systemic comorbidities, like cardiovascular disease,
associated with psoriasis may suggest systemic as well as lesional
psoriatic gene expression signatures, our results did not reveal
broad-scale inﬂammatory changes in the blood. The overlap be-
tween the psoriatic blood DEGs reported here and the results of
two gene expression studies comparing patients with coronary
artery disease to controls [16,17] was also poor. Nonetheless, car-
diovascular risk in psoriasis was initially documented in hospital-
ized subjects [41–43] and the subsequent community based
studies reported a stronger association with severe psoriasis
[44–46]. It is possible that dysregulation in the peripheral blood of
severe cases, in contrast to the mild–moderate cases included in
our analysis, may involve a different set of genes associated with
systemic response. Larger studies enrolling subjects in deﬁned sub-
groups that would enable further stratiﬁcation based on disease se-
verity, along with age of onset, morphology and response to therapy
which aim to investigate the differential gene expression not only in
psoriatic skin but also in the blood will be important to help illumi-
nate the molecular genetic basis of the extensive disease heteroge-
neity and systemic involvement seen in psoriasis.
For the past two decades, familial linkage analysis and genome
wide association studies have suggested nearly forty psoriasis sus-
ceptibility loci [19,21,23,24,29]. Twelve of these (PSORS1-12) have
been conﬁrmed by multiple studies in different populations. How-
ever, no susceptibility gene has been deﬁnitively conﬁrmed within
these regions, except for very strong evidence provided by Nair
et al. for HLA-Cw6 at PSORS1 locus [47]. Focus on DEGs reported
by microarray analysis may provide a new strategy to pinpoint the
susceptibility genes in the broader regions detected by genome
studies. In fact, in a recent report Chen et al. demonstrated differen-
tially expressed genes to be more likely to harbor disease-related
mutations [14]. Thus, merging of transcriptional and genetic
datasets may facilitate the identiﬁcation of the comprehensive set
of psoriasis susceptibility genes, as transcriptional changes may, at
least in some cases, reﬂect the functional results of genetic varia-
tions associated with the disease. For this purpose, we examined
the list of DEGs corresponding to reported susceptibility loci.
Genes replicated across the microarray studies that map to the
PSORS loci may be especially notable as the chances of a gene to
be associated with disease increased with the number of studies
reporting the gene [14]. This data may provide a useful guide to
pinpoint psoriasis-associated genes within these regions.
We found several overlaps between previously reported suscepti-
bility loci and genomic or chromosomal locations of transcriptional
“hot spots” we detected in both our set of DEGs and the set of DEGs
that are replicated across studies. At chromosomal region 1q21,
where both PSORS4 and the epidermal differentiation complex
(EDC) are mapped [48], loricrin (LOR), involucrin (IVL), SPRR family
and calcium binding S100 family genes have been consistently repli-
cated DEGs. While associations between psoriasis and a number of
genes at this region have been reported, there has been no conclusive
evidence in any case. DEGs overlapping to this region may suggest
possible new linkages at this locus. Our set of skin DEGs also showed
signiﬁcant accumulation at 5q31.1, overlapping with PSORS11.One of the signiﬁcant regions for both our skin and blood datasets
was also signiﬁcant for the set of genes replicated across microarray
studies. At chromosomal region 11q12.1-q13.2, we detected immune
related genes TCIRG1, OTUB1, RBM4 and UBE2L6 along with RELA, a
component of the NFκB pathway in our skin dataset. Replicated
genes in this region also included FADS1, FADS2, CST6, GAL and
CCND1. This region was also reported to contain a balanced transloca-
tion in two of the 477 psoriatic subjects in a cytogenetic analysis [49],
Examination of transcriptionally dysregulated genes within reported
susceptibility loci offers a new strategy to narrow the search for can-
didates in future genetic analyses.
In summary, our data extend the support for major pathway
disturbances related to epidermal hyperproliferation in the lesional
psoriatic skin. The set of genes replicated across studies presents a com-
prehensive picture of dysregulated pathways in psoriasis that may not
be evident in the analyses of individual datasets. We also elucidate the
gene expression proﬁles in the blood of mild–moderate cases, which
contain several genes related to previously implicated pathways in pso-
riasis. Investigation of gene expression alterations in the blood of severe
casesmay further illuminatemolecular pathways related to the system-
ic effects of psoriasis. Transcriptional analysis can be expected to aid in
the development of tools for themolecular classiﬁcation of diseasewith
diagnostic and possibly prognostic value. Furthermore, the pool of pso-
riasis associated skin and blood DEGs should provide guidance to focus
future candidate gene screenings for the precise localization of disease
susceptibility loci.
4. Methods
4.1. Samples
Nine subjects (6 females, 3 males), aged between 32 and 77 years,
with a clinical diagnosis of psoriasis vulgaris were recruited from the
Dermatology Outpatient Clinic of New York Presbyterian Hospital,
Cornell University (IRB # 0998-398). All patients had mild–moderate
chronic plaque psoriasis, did not have a history of systemic treatment
for psoriasis, were free of phototherapy at least for one month prior to
the biopsy date and had PASI scoresb12. After obtaining informed
consent, a total of four 6 mm punch biopsy samples, two from psori-
atic lesions and two from site-matched nonlesional skin were taken
from each of the nine subjects. All skin samples were snap frozen in
liquid nitrogen. Additionally, blood samples from 8 psoriasis (3 fe-
males, 5 males, aged between 27 and 72 years) and 5 nonpsoriatic
control subjects (2 females, 3 males, aged between 23 and 63 years)
were also collected and frozen at −80 °C.
4.2. RNA extraction and biotinylated cRNA preparation
Peripheral blood mononuclear cells were isolated from blood sam-
ples with the use of Ficoll gradients (Amersham Biosciences,
Piscataway, NJ). Total RNA extraction from the tissue and blood sam-
ples was performed using TRIzol reagent (Invitrogen Corporation,
Carlsbad, CA). RNeasy Mini kit (QIAGEN Inc, Valencia, CA) was used
for RNA puriﬁcation. Microarray assays were processed according to
the Affymetrix GeneChip Expression Analysis Technical Manual
(Affymetrix, Santa Clara, CA, http://www.affymetrix.com). Using
16 μg of total RNA, double stranded cDNA was synthesized to be pu-
riﬁed and concentrated by ethanol precipitation. Biotinylated cRNA
was produced by in vitro transcription and fragmented to 50–200 nu-
cleotides. The labeled cRNA was hybridized for 16 h at 45 °C to
Affymetrix HG-U95A or HG-U95Av2 microarrays, which contain ap-
proximately 12600 probe sets. After washing the microarrays,
streptavidin-phycoerythrin staining was performed. The staining
was ampliﬁed using biotinylated anti-streptavidin and streptavidin-
phycoerythrin for scanning (HP GeneArray Scanner, Affymetrix).
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Microarray Suite v5.0 (Affymetrix Inc., Santa Clara, CA) was used
to generate DAT and CEL ﬁles, which were imported to dChip using
a probe set mask ﬁle to combine data from HG-U95A and HG-
U95Av2 arrays. After applying the probe set mask, analyses were car-
ried out using 12577 probe sets corresponding to 9748 unique genes.
CEL image ﬁles were checked for hybridization artifacts in dChip be-
fore and after normalization and model based expression index
(MBEI) calculation. All arrays were normalized using the invariant
set method. MBEI were calculated in dChip by ﬁtting the model to
the PM–MM differences across all arrays. Arrays ﬂagged as outliers
were removed from the dataset and the normalization was repeated
for the remaining arrays until achieving a sample with no outliers.
Final dataset comprised a total of 21 arrays, which include 10 skin
samples (5 lesional and 5 nonlesional from 5 psoriatic patients) and
11 blood samples (6 psoriatic and 5 from nonpsoriatic subjects).
4.4. Unsupervised hierarchical cluster analysis and differential gene
expression
Probe sets were ﬁltered to identify the most informative set to be
used in unsupervised cluster analysis. Probes that were called present
in at least 30% of the arrays and those with a coefﬁcient of variation
greater than 0.3 were included in unsupervised clustering. There
were 3832 probes fulﬁlling these criteria, which corresponded to
3412 unique genes. A two-way cluster analysis was performed on
the probe sets that passed the ﬁlter in dChip using centroid linkage
and the 1-r metric.
Differentially expressed probe sets between cases (lesional skin
and psoriatic blood) and controls (nonlesional skin and nonpsoriatic
blood) were deﬁned according to i) having a present call in at least
2 arrays among either cases or controls and ii) having a p≤0.01 in
the two tailed t-test (paired for skin and unpaired for blood samples)
between log2 transformed MBEI from case and control arrays AND
passing the designated Benjamini–Hochberg critical values.
Enrichment of gene ontology (GO) terms was tested for signiﬁ-
cance in dChip (p≤0.001), which uses the binomial approximation
to the hypergeometric distribution to calculate p values. The degree
of enrichment for a GO term was assessed by calculating the odds
ratio for enrichment of a given GO term in a speciﬁed gene list. DEGS
were annotated for immune related functions manually using the on-
line sources at www.pubmed.org Entrez Gene pages and using the GO
terms provided by dChip and the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) website (www.david.abcc.
ncifcrf.gov) [50].
4.5. Quantitative real time reverse transcriptase polymerase chain reaction
(QRT-PCR) validation
Total RNA from skin samples, where sufﬁcient amounts of total
RNA were available after microarray analysis, was used for QRT-PCR
analysis to conﬁrm the validity of microarray analysis for 8 randomly
selected genes in the skin (TGM1, POLE3, IVL, FABP5, IL1RN, LYN, GARS
and ALOX12B). Primers for these genes were designed using Primer
Express software.18S rRNA was used as an internal control. The
resulting fold changes were compared to those obtained by microar-
ray analysis.
4.6. Query for microarray studies
We ran a query in PubMed using the search terms ‘psoriasis AND
microarray’ and ‘psoriasis AND gene expression array’ to ﬁnd studies
performed on psoriatic subjects using microarray methods in order to
form a comparison group for our data. We excluded the studies that
did not involve a lesional vs nonlesional comparison or provide aglobal, as opposed to pathway speciﬁc, list of dysregulated genes.
Of the nine studies we detected, we further excluded the study by
Bowcock et al. [5] since the same samples were also used in a later
analysis by Zhou et al. [4], which is included in our comparison group.
Results of the analysis by Romanowska et al. [30] were not included be-
cause the presented list contained only those genes also reported by
Zhou et al. Results of the remaining 8 studies by Oestreicher et al. [6],
Zhou et al. [4], Kulski et al. [7], Mee et al. [12], Reischl et al. [11], Yao
et al. [10], Gudjonsson et al. [9] and Suarez-Farinas et al. [13] weremer-
ged together to form a comparison group. DEGs detected in involved vs.
nonpsoriatic skin comparisons reported by three of these studies, by
Zhou et al., Kulski et al. and Gudjonsson et al., were also merged to
form a third group of genes. The reported lists of genes, and the full
lists whenever provided by the contacted authors, were ﬁltered to in-
clude only those genes present on the HU-G95A array. Merging of the
lists was accomplished by identifying all probes assigned to the Entrez
Gene ID of any reported probe. Unigene accession numbers were used
to identify the associated probes where reported probe did not have
an assigned Entrez Gene ID.
We also searched for microarray studies comparing psoriatic and
nonpsoriatic blood with the same criteria. In addition to a number
of investigations analyzing the treatment effects on gene expression
in psoriatic blood before and after treatment, there was only one mi-
croarray study directly comparing gene expression between psoriatic
and nonpsoriatic blood. We used the list of most strongly dys-
regulated genes provided in this publication to compare our blood
data, as we could not access the full list of dysregulated genes.
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